Loss-of-function mutations in SLC30A8 protect against type 2 diabetes
Loss-of-function mutations protective against human disease provide in vivo validation of therapeutic targets, but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of ∼150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating varia...
| Príomhchruthaitheoirí: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formáid: | Journal article |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
Nature Publishing Group
2014
|
| _version_ | 1826259911137296384 |
|---|---|
| author | Flannick, J Thorleifsson, G Beer, N Jacobs, S Grarup, N Burtt, N Mahajan, A Fuchsberger, C Atzmon, G Benediktsson, R Blangero, J Bowden, D Brandslund, I Brosnan, J Burslem, F Chambers, J Cho, Y Christensen, C Douglas, D Duggirala, R Dymek, Z Farjoun, Y Fennell, T Fontanillas, P Forsén, T |
| author_facet | Flannick, J Thorleifsson, G Beer, N Jacobs, S Grarup, N Burtt, N Mahajan, A Fuchsberger, C Atzmon, G Benediktsson, R Blangero, J Bowden, D Brandslund, I Brosnan, J Burslem, F Chambers, J Cho, Y Christensen, C Douglas, D Duggirala, R Dymek, Z Farjoun, Y Fennell, T Fontanillas, P Forsén, T |
| author_sort | Flannick, J |
| collection | OXFORD |
| description | Loss-of-function mutations protective against human disease provide in vivo validation of therapeutic targets, but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of ∼150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating variants in SLC30A8, which encodes an islet zinc transporter (ZnT8) and harbors a common variant (p.Trp325Arg) associated with T2D risk and glucose and proinsulin levels. Collectively, carriers of protein-truncating variants had 65% reduced T2D risk (P = 1.7 × 10 -6), and non-diabetic Icelandic carriers of a frameshift variant (p.Lys34Serfs*50) demonstrated reduced glucose levels (-0.17 s.d., P = 4.6 × 10 -4). The two most common protein-truncating variants (p.Arg138* and p.Lys34Serfs*50) individually associate with T2D protection and encode unstable ZnT8 proteins. Previous functional study of SLC30A8 suggested that reduced zinc transport increases T2D risk, and phenotypic heterogeneity was observed in mouse Slc30a8 knockouts. In contrast, loss-of-function mutations in humans provide strong evidence that SLC30A8 haploinsufficiency protects against T2D, suggesting ZnT8 inhibition as a therapeutic strategy in T2D prevention. © 2014 Nature America, Inc. |
| first_indexed | 2024-03-06T18:57:18Z |
| format | Journal article |
| id | oxford-uuid:1246416e-726f-4534-a833-da0ce8865f5c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:57:18Z |
| publishDate | 2014 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:1246416e-726f-4534-a833-da0ce8865f5c2022-03-26T10:07:04ZLoss-of-function mutations in SLC30A8 protect against type 2 diabetesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1246416e-726f-4534-a833-da0ce8865f5cEnglishSymplectic Elements at OxfordNature Publishing Group2014Flannick, JThorleifsson, GBeer, NJacobs, SGrarup, NBurtt, NMahajan, AFuchsberger, CAtzmon, GBenediktsson, RBlangero, JBowden, DBrandslund, IBrosnan, JBurslem, FChambers, JCho, YChristensen, CDouglas, DDuggirala, RDymek, ZFarjoun, YFennell, TFontanillas, PForsén, TLoss-of-function mutations protective against human disease provide in vivo validation of therapeutic targets, but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of ∼150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating variants in SLC30A8, which encodes an islet zinc transporter (ZnT8) and harbors a common variant (p.Trp325Arg) associated with T2D risk and glucose and proinsulin levels. Collectively, carriers of protein-truncating variants had 65% reduced T2D risk (P = 1.7 × 10 -6), and non-diabetic Icelandic carriers of a frameshift variant (p.Lys34Serfs*50) demonstrated reduced glucose levels (-0.17 s.d., P = 4.6 × 10 -4). The two most common protein-truncating variants (p.Arg138* and p.Lys34Serfs*50) individually associate with T2D protection and encode unstable ZnT8 proteins. Previous functional study of SLC30A8 suggested that reduced zinc transport increases T2D risk, and phenotypic heterogeneity was observed in mouse Slc30a8 knockouts. In contrast, loss-of-function mutations in humans provide strong evidence that SLC30A8 haploinsufficiency protects against T2D, suggesting ZnT8 inhibition as a therapeutic strategy in T2D prevention. © 2014 Nature America, Inc. |
| spellingShingle | Flannick, J Thorleifsson, G Beer, N Jacobs, S Grarup, N Burtt, N Mahajan, A Fuchsberger, C Atzmon, G Benediktsson, R Blangero, J Bowden, D Brandslund, I Brosnan, J Burslem, F Chambers, J Cho, Y Christensen, C Douglas, D Duggirala, R Dymek, Z Farjoun, Y Fennell, T Fontanillas, P Forsén, T Loss-of-function mutations in SLC30A8 protect against type 2 diabetes |
| title | Loss-of-function mutations in SLC30A8 protect against type 2 diabetes |
| title_full | Loss-of-function mutations in SLC30A8 protect against type 2 diabetes |
| title_fullStr | Loss-of-function mutations in SLC30A8 protect against type 2 diabetes |
| title_full_unstemmed | Loss-of-function mutations in SLC30A8 protect against type 2 diabetes |
| title_short | Loss-of-function mutations in SLC30A8 protect against type 2 diabetes |
| title_sort | loss of function mutations in slc30a8 protect against type 2 diabetes |
| work_keys_str_mv | AT flannickj lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT thorleifssong lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT beern lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT jacobss lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT grarupn lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT burttn lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT mahajana lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT fuchsbergerc lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT atzmong lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT benediktssonr lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT blangeroj lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT bowdend lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT brandslundi lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT brosnanj lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT burslemf lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT chambersj lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT choy lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT christensenc lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT douglasd lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT duggiralar lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT dymekz lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT farjouny lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT fennellt lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT fontanillasp lossoffunctionmutationsinslc30a8protectagainsttype2diabetes AT forsent lossoffunctionmutationsinslc30a8protectagainsttype2diabetes |